IMU

5.56%

5.7¢ imugene limited

I didn't invest in HER-Vaxx which was in Ph2 clinical trial so...

First 119 Last

Share
Profile

Follow
AlCp

26,687 Posts.

1732

16/04/24

10:24

Post #: 73363187
Share

Originally posted by fourdollars ↑

"I would be very happy if you could enlighten me with your thought about why FDA has granted the designation if even a regular hot copper poster can see this is a failing trial?"

Not sure what you are asking. The FDA grant fast-track designation for trials that are for diseases with poor prognoses and limited treatment options. This is the case with bile duct cancer. The "fail" is that IMU management was expecting to be able to add additional indications to its expansion trial but haven't been able to do so.

But really you: "they do not realise it’s still a speculative stock, ..... still in early phase 1"

and my good mate@AICp: "Bruh, the clinical trial are in the early Ph1."

have summed up the situation well.

IMU has gone backwards from being at advanced Phase II to early Phase I, and its SP has logically reflected this.

That's the "follow the science" perspective.

Added to the science are Hopper's cap raise shenanigans and Leslie's long-term over-promising and under-delivering.

Its all a matter of perspective. From my perspective, taking on a manufacturing facility with 50 staff and the associated capraise was spectacularly stupid. Nothing to do with the company's objectives and supposed skill set. Now, just 8 months later it basically gives the facility away and we get from Leslie:

"Moreover, this partnership allows us to focus on our keycapabilities, namely the development of novel cancer treatments."

Really? So would not have taking it on in the first place.

Others think that its a genius move, because "look at all the cash IMU is saving" - so its a "positive price sensitive announcement".

I see it as reminding the market of management's incompetence and scatter-gun strategy - so expect more price weakness off the back of this announcement.

Expand

I didn't invest in HER-Vaxx which was in Ph2 clinical trial so what's your point??? Do you want to respond to what efficacy you aren't seeing in Ph1 clinical trial for CF33?????

Last edited by AlCp: 16/04/24

IMU Price at posting: 8.8¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

RCE

Recce's R327 found effective against E.coli during clinical trial

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

There are more pages in this discussion • 45 more messages in this thread...

First 119 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.7¢		Change 0.003(5.56%)		Mkt cap ! $417.2M

Open	High	Low	Value	Volume
5.5¢	5.8¢	5.2¢	$2.499M	45.00M

Buyers (Bids)

No.	Vol.	Price($)
2	1921794	5.6¢

Sellers (Offers)

Price($)	Vol.	No.
5.7¢	1368288	7

View Market Depth

No.	Vol.	Price($)
2	1921794	0.056
5	286362	0.055
12	3517552	0.054
17	2756044	0.053
23	2021898	0.052

Price($)	Vol.	No.
0.057	1368288	7
0.058	2564048	15
0.059	3137099	10
0.060	2176188	16
0.061	1460386	7

Last trade - 16.10pm 28/06/2024 (20 minute delay)

IMU (ASX) Chart

I didn't invest in HER-Vaxx which was in Ph2 clinical trial so...

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Recce's R327 found effective against E.coli during clinical trial

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I didn't invest in HER-Vaxx which was in Ph2 clinical trial so...

Top Stories

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Recce's R327 found effective against E.coli during clinical trial

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News